Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi

 
• By Mandy Jackson
  
Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.
Rozlytrek will compete with Vitrakvi for NTRK gene fusion patients. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip